Ibrutinib (Imbruvica) for Leukemia


( Last Updated : July 17, 2019)
Generic Name:
Ibrutinib
Manufacturer:
Janssen Canada Inc.
Brand Name:
Imbruvica
Project Line:
Reimbursement Review

Details


Tumour Type:
Leukemia
Indications:
In combination with rituximab for previously untreated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Leukemia (SLL); In combination with obinutuzumab for previously untreated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Leukemia (SLL)
Review Status:
Not Filed
Clarification:
CADTH is unable to recommend reimbursement of the relevant product because a submission to CADTH was not filed by the manufacturer.

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.